Navidea Biopharmaceuticals, Inc. (NAVB) Sees Large Drop in Short Interest

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) was the target of a large decline in short interest in the month of March. As of March 29th, there was short interest totalling 4,134,851 shares, a decline of 3.0% from the March 15th total of 4,263,411 shares. Based on an average daily trading volume, of 141,534 shares, the days-to-cover ratio is currently 29.2 days. Approximately 2.7% of the shares of the company are short sold.

NYSEAMERICAN NAVB opened at $0.31 on Friday. Navidea Biopharmaceuticals has a twelve month low of $0.29 and a twelve month high of $0.68.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter. The business had revenue of $0.40 million during the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%.

TRADEMARK VIOLATION NOTICE: “Navidea Biopharmaceuticals, Inc. (NAVB) Sees Large Drop in Short Interest” was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply